前列腺素E_1抗肝纤维化的临床疗效观察

Clinical efficacy of prostaglandin E_1 for antifibrosis

目的 观察前列腺素E1对活动性肝炎肝硬化的抗纤维化疗效。方法 将 10 0例患者随机分为两组 ,治疗组 5 0例以PGE16 0 μg加入 10 %葡萄糖 2 5 0ml中静滴 ,1次 /d ,疗程 30d。对照组以门冬氨酸钾镁 30ml加入 10 %葡萄糖中 2 5 0ml静滴 ,1次 /d ,疗程相同。两组患者性别、年龄和肝功能均有可比性。治疗前后以放射免疫法检测血清HA、IVC、LN ,B超探测脾脏厚度。结果 治疗组血清HA、IVC以及LN水平明显降低 ,与治疗前及对照组相比较差异有非常显著性 (P<0 .0 1) ,治疗组 5 0 %病例脾脏缩小。结论 PGE1能明显降低肝炎肝硬化患者血清HA、IVC、LN水平 ,且脾脏缩小 ,有一定抗纤维化作用。

Objective To study the efficacy of prostaglandin E 1(PEG 1)for antifibrosis on active hepatic cirrhosis.Methods 100 patients were divided into two groups.The treated group(50 patients) was given PGE 1 60 μg/d,The control group was given Potassium magnesium Aspartate 30 ml/d.The therapy lasted for 30 days.Serum level of HA?IVC?LN by radioimmunoassay(RIA) and thickness of spleen were detected by ultrasonics before and after the treatment.Results In treated group, the serum HA, IVC, LN levels significantly decreased(P<0.01).The thickness of spleens 50 percent of patients were found in decreased.Conclusions PGE 1 had the effect of antifibrosis on active hepatic cirrhosis.